A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or platinum-resistant ovarian cancer (OC).
Colin D. Weekes
Consultant or Advisory Role - Genentech
Research Funding - Genentech
Laetitia E. Lamberts
Research Funding - Genentech
Mitesh J. Borad
No relevant relationships to disclose
Johannes Voortman
Research Funding - Genentech
Robert R. McWilliams
No relevant relationships to disclose
Jennifer Robinson Diamond
No relevant relationships to disclose
Elisabeth De Vries
Research Funding - Genentech
Henk M.W. Verheul
Research Funding - Genentech
Christopher Hanyoung Lieu
No relevant relationships to disclose
Huibin Yue
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Yulei Wang
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Suzie Scales
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Divya Samineni
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Katie Wood
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Flavia Brunstein
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Daniel J. Maslyar
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
George P. Kim
No relevant relationships to disclose